April 15 (Reuters) - The European Medicines Agency said on
Thursday it is reviewing available data on the use of
GlaxoSmithKline's monoclonal antibody to treat COVID-19
patients.
The agency said its review of VIR-7831 will include data
from a study comparing its effect with that of a placebo in
patients with mild to moderate COVID-19 who were at high risk of
progressing to a more severe condition. (https://bit.ly/3n0spGx)
A more comprehensive rolling review is expected to start at
a later time, the agency said.
(Reporting by Vishwadha Chander in Bengaluru; Editing by
Bernard Orr)